Welcome to our dedicated page for Bionano Genomics news (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics stock.
Bionano Genomics, Inc. (Nasdaq: BNGO) is a pioneering company in the life sciences instrumentation sector, dedicated to advancing genome biology understanding through innovative solutions. The company is renowned for its development and marketing of the Saphyr™ system, an ultra-sensitive platform designed for structural variation detection. This system enables researchers and clinicians to accelerate diagnostics and therapeutic target discovery, streamlining studies on chromosomal changes.
Bionano's core mission is to transform genomic analysis through optical genome mapping (OGM) solutions, diagnostic services, and software. Their flagship product, Saphyr™, offers unmatched capabilities in structural variation discovery and the ability to construct comprehensive genome assemblies. This technology is crucial for applications in cancer research, human disease studies, agricultural bioengineering, and genome discovery.
Recent achievements include the detection of unique structural variations and gene fusions in blood cancer samples, underscoring OGM's potential as a complement to traditional sequencing methods. Bionano's OGM technology has shown superior sensitivity and resolution in various studies, highlighting its utility in pediatric leukemia and other cancers.
The company operates globally with significant revenue from the Americas, and it generates product revenue from the sales of OGM and Ionic Purification systems and consumables. Bionano also offers diagnostic testing for neurodevelopmental disabilities through its Lineagen, Inc. d/b/a Bionano Laboratories business and industry-leading genome analysis software that integrates next-generation sequencing and microarray data.
Partnerships with AI-driven companies like Diagens further enhance Bionano's offerings, aiming to improve reproductive health and other clinical applications. Additionally, Bionano continuously upgrades its VIA software and Bionano Solve pipeline to provide researchers with precise and sensitive genomic research tools.
For more information, visit Bionano Genomics and its associated websites, www.bionanolaboratories.com and www.purigenbio.com.
Bionano Genomics (BNGO) reported promising interim results from its ongoing clinical trial to evaluate optical genome mapping (OGM) as a potential new standard of care (SOC) for genetic disease diagnosis. The study involved 331 sample runs across 202 subjects, achieving 97.7% concordance with SOC. Key findings include a first-pass success rate of 94% and 100% concordance for pathogenic variant calls. The trial enrolled 813 subjects overall, with the expectation of impactful outcomes that could revolutionize genetic testing practices.
Bionano Genomics (BNGO) announced its upcoming virtual Symposium from January 10-13, 2022, featuring 31 oral presentations from 27 customers worldwide. This annual event will highlight the applications of optical genome mapping (OGM) in genetic disease and cancer research.
With 45% of presentations from North America and 55% from Europe, participants will explore OGM's role across various domains, including constitutional cytogenomics and hematologic malignancies.
Registration is free and aims to connect OGM users and demonstrate advancements in genomic analysis.
Bionano Genomics (BNGO) announced the completion of its first prototype for a new single molecule imaging system aimed at improving optical genome mapping (OGM). This prototype will be tested to meet the demands of high-volume users, with the commercial system projected for release in the first half of 2023. The new system is expected to significantly enhance throughput, imaging up to 820 Gbp per hour compared to the current Saphyr system’s 205 Gbp. It will also offer flexible workflows, allowing simultaneous processing of diverse samples.
Bionano Genomics (BNGO) has announced that University Hospitals Leuven in Belgium has expanded its BELAC-accredited menu to include assays for acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and facioscapulohumeral muscular dystrophy (FSHD). This expansion follows their previous accreditation for acute lymphoblastic leukemia (ALL) analyses. The new optical genome mapping (OGM) workflows significantly reduced costs and turnaround times while increasing the success rates in identifying pathogenic variants. Bionano's CEO believes this achievement sets a precedent for other labs to adopt OGM.
Bionano Genomics, Inc. (BNGO) announced the appointment of Vincent Wong to its board of directors. Mr. Wong has extensive experience in commercial leadership, including nearly 18 years at Roche Diagnostics, where he held senior roles in product marketing, sales, and business development. His expertise is expected to enhance Bionano's commercial execution and market access strategies for its optical genome mapping solutions. CEO Erik Holmlin expressed optimism about Wong's contribution to the company’s growth and innovation in genomics.
Bionano Genomics (BNGO) launched version 6.1 of BioDiscovery’s NxClinical software, enhancing analysis of next-generation sequencing (NGS) data for genetic diseases and cancer. This update introduces improved detection of clinically relevant variants with new uniparental disomy functionality and an expanded sequence knowledgebase. The software streamlines data interpretation using automated annotations per ACMG standards, reducing reporting time. The initiative aims to integrate optical genome mapping (OGM) with NGS data to provide a comprehensive view of genomic variations.
Bionano Genomics (BNGO) is hosting its 2022 Symposium virtually from January 10-13, featuring 25 customers presenting on Optical Genome Mapping (OGM) applications in genetic diseases and cancer. Following the success of last year's event with over 4,500 attendees, this year's Symposium aims to showcase a broader range of applications, including a dedicated day for OGM and Next-Generation Sequencing (NGS). The event will include oral presentations, panel discussions, and scientific poster exhibits, emphasizing OGM's potential in clinical and translational research.
Bionano Genomics (BNGO) announced a study published in Blood from The University of Texas MD Anderson Cancer Center, showcasing the efficacy of Optical Genome Mapping (OGM) in assessing structural variations in myelodysplastic syndrome (MDS). The study involving 76 subjects revealed that OGM offers a higher resolution and faster analysis compared to traditional methods like karyotyping, with a 100% concordance rate. OGM identified 23 clinically significant structural variants that were undetected by karyotyping, underscoring its potential as a standard for structural variant profiling.
Bionano Genomics (BNGO) has appointed Keith Gligorich, PhD, as the new VP Operations for Bionano Laboratories. Gligorich, previously with Guardant Health, brings over a decade of experience in molecular diagnostics and laboratory operations. His role will focus on expanding the lab's offerings to include CLIA-certified and CAP-accredited services, including laboratory developed tests (LDTs) for genetic diseases and hematologic malignancies. This strategic move aims to enhance Saphyr adoption and develop reimbursement pathways with insurance companies.
Bionano Genomics (BNGO) announced a study from Johns Hopkins University published in the Journal of Clinical & Anatomic Pathology, highlighting the effectiveness of optical genome mapping (OGM) in cancer analysis. The study found that OGM achieved a sensitivity of 96% for copy number variants (CNVs) and 100% for structural variations (SVs) when compared to traditional methods. OGM revealed additional CNVs and SVs not detected by conventional techniques, showing potential in refining cancer diagnosis and identifying therapeutic targets. This positions OGM as a valuable alternative to existing genomic analysis methods.
FAQ
What is the current stock price of Bionano Genomics (BNGO)?
What is the market cap of Bionano Genomics (BNGO)?
What does Bionano Genomics, Inc. specialize in?
What is the Saphyr™ system?
What are the applications of Bionano's OGM technology?
What recent achievements has Bionano reported?
Where does Bionano operate?
What additional services does Bionano offer?
Who are Bionano's key partners?
What is the purpose of Bionano's VIA software?
Are Bionano's products for research or clinical use?
How can I learn more about Bionano Genomics?
